Anxiety disorders
- PMID: 33581801
- PMCID: PMC9248771
- DOI: 10.1016/S0140-6736(21)00359-7
Anxiety disorders
Erratum in
-
Department of Error.Lancet. 2021 Mar 6;397(10277):880. doi: 10.1016/S0140-6736(21)00473-6. Lancet. 2021. PMID: 33676627 No abstract available.
Abstract
Anxiety disorders form the most common group of mental disorders and generally start before or in early adulthood. Core features include excessive fear and anxiety or avoidance of perceived threats that are persistent and impairing. Anxiety disorders involve dysfunction in brain circuits that respond to danger. Risk for anxiety disorders is influenced by genetic factors, environmental factors, and their epigenetic relations. Anxiety disorders are often comorbid with one another and with other mental disorders, especially depression, as well as with somatic disorders. Such comorbidity generally signifies more severe symptoms, greater clinical burden, and greater treatment difficulty. Reducing the large burden of disease from anxiety disorders in individuals and worldwide can be best achieved by timely, accurate disease detection and adequate treatment administration, scaling up of treatments when needed. Evidence-based psychotherapy (particularly cognitive behavioural therapy) and psychoactive medications (particularly serotonergic compounds) are both effective, facilitating patients' choices in therapeutic decisions. Although promising, no enduring preventive measures are available, and, along with frequent therapy resistance, clinical needs remain unaddressed. Ongoing research efforts tackle these problems, and future efforts should seek individualised, more effective approaches for treatment with precision medicine.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Figures
Comment in
-
Benzodiazepines for the long-term treatment of anxiety disorders?Lancet. 2021 Jul 10;398(10295):119-120. doi: 10.1016/S0140-6736(21)00934-X. Lancet. 2021. PMID: 34246344 No abstract available.
-
Benzodiazepines for the long-term treatment of anxiety disorders? - Authors' reply.Lancet. 2021 Jul 10;398(10295):120. doi: 10.1016/S0140-6736(21)00931-4. Lancet. 2021. PMID: 34246346 Free PMC article. No abstract available.
References
-
- Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 718–79. - PubMed
-
- Batelaan NM, Rhebergen D, de Graaf R, Spijker J, Beekman ATF, Penninx BWJH. Panic attacks as a dimension of psychopathology. J Clin Psychiatry 2012; 73: 1195–202. - PubMed
-
- Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 2011; 72: 341–48. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
